预约演示
Sanofi advances NK cell engager to Phase II for blood cancer treatment
临床2期引进/卖出免疫疗法并购
NKs are involved in the body’s first line of immune defence, which can recognise and destroy cancer cells. Image credit: Shutterstock/Juan Gaertner.
Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase canceral evaluating the drug’s use in treating a range of blood cancers.
Sanofiugmaker dosed the first patient in the Phase II part of the Phase I/II trial (NCT05086315), according to a 15 April 2024, press release by researblood cancersnate Pharma.
The trial will investigate the therapy’s safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity in various haematological malignancies.Innate Pharma
The non-randomised trial is estimated to enrol 126 patients with diseases including relapsed or refractory acute myeloid lhaematological malignancieshoblastic leukaemia and high risk-myelodysplasia, amongst others.
Innate and Sanofi initially entered a research collaboration and license agreement irelapsed or refractory acute myeloid leukaemiaogB-cell acute lymphoblastic leukaemia from Innate inmyelodysplasia.5m) milestone payment structured deal.
BeyondSpring gets grant for treating cancer expressing mutant ras protein with plinabulin
BeyondSpringaceuticals gets grant forcancerating interleukin-2-inducible T-cellplinabulin
As part of the deal, Sanofi is responsible for the development, manufacturing and commercialisation duties of assets produced via the collaboration.
Corvus Pharmaceuticals79/IPH6101 to the Phase II interleukin-2-inducible T-cell kinase(€4m) in a milestone payment.
Innate’s chief medical officer Dr. Sonia Quaratino said: “The progression of SAR443579 to the Phase II expansion part of the clinical trial in blood cancers is another step in bringing this innovative NK cell engager to patients.”
SAR443579/IPH6101 is Sanofi46/CD16-based NK cell engager developed using Innate’s antibody-based NK cell Engager Therapeutics (ANKET) platform. NKs are involved in the body’s first line of immune defence, which can recognise and destroy cancer cells. Innate is developing therapies that activate NK cell receptors such as CD16 and NKp46. Other approaches include preventing NK inactivation by blocking inhibitory checkpoint receptors.
The other ANKET molecule licensed by Sanofi in 2016 was Sanofi01, currently in Phase II trials for relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory Light-chain amyloidosis (RRLCA).
Innate and Sanofi expanded their partnership in 2022, allowing the latter comSAR443579icense additional targets. As part of the expanded deal, blood cancerscensed IPH62 and IPH67, with the option for one additional target. The deal included a $26.64m upfront payment and a potential $1.44bn in developmental, regulatory, and commercial milestones, as well as royalties on potential net sales.
Sanofi plans to spin outNKp46/CD16-basederapy biotech this year when it aInnateto acquire Inhibrx for $1.7bn. Whilst the drugmaker will directly take on one of Inhibrx’s drugs for a rare inherited disease, it will spin off the biotech’s cancerancer drInnateto a new entity. The company, dubbed New Inhibrx, will start its CD16ney iNKp46 cancer therapeutic space with $200m in cash. The deal is expected to close in Q2 2024.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。